Clinical Research Directory

MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial

This pilot clinical trial will study psilocybin-assisted therapy for adults with advanced cancer who are experiencing demoralization, existential distress, or related psychological concerns. Demoralization can include feelings of hopelessness, helplessness, loss of meaning, and distress related to illness or end of life. The purpose of this study is to assess whether a hybrid group-based psilocybin-assisted therapy program is feasible, acceptable, and safe in adults with advanced cancer. The study will also explore which combination of psilocybin dose and psychotherapy approach may be most promising for a future larger trial. Participants will be randomly assigned by wave to one of four intervention combinations: 25 mg psilocybin with mindfulness-based psilocybin-assisted therapy, 25 mg psilocybin with standard psilocybin-assisted therapy, 5 mg psilocybin with mindfulness-based psilocybin-assisted therapy, or 5 mg psilocybin with standard psilocybin-assisted therapy. The psilocybin dose will be blinded, meaning participants and some members of the study team will not know which dose was assigned. Psychotherapy approach will not be blinded. The study will enroll at least 60 participants across Calgary and Kingston.

Existential and Solution-Focused Group Intervention for Older Adults

This study aims to evaluate the effectiveness of an integrated existential and solution-focused group intervention enriched with narrative therapy techniques in promoting active aging among older adults. The intervention was developed to address psychosocial limitations associated with aging, including social isolation, role loss, ageism, and existential concerns. The study employed an embedded mixed-methods randomized controlled design. Older adults aged 65 years and over who attended a primary healthcare mental health unit in a city, Türkiye, were randomly assigned to either an intervention group or a control group. Participants in the intervention group received a structured 10-session group program combining existential therapy, solution-focused approaches, and narrative therapy techniques. Quantitative data were collected using the World Health Organization Quality of Life-Old Module (WHOQOL-OLD) and the Active Aging Scale (AAS) at baseline, post-intervention, and three-month follow-up. Qualitative data were obtained through session transcripts and field notes to explore participants' experiences and the intervention process.

AI Assisted Personalized Legacy Program (Reflections: My Story) for Patients With Serious Illness

The purpose of this study is to determine if it is feasible and acceptable to recruit for and deliver the AI Assisted Personalized Legacy Program intervention to patients with serious illness.

Lysergic Acid Diethylamide (LSD) in Palliative Care

Background: Terminally ill patients often experience significant psychosocial distress having depressed mood, death anxiety, pain, and an overall poor quality of life. Recent evidence from pilot studies suggests that serotonergic hallucinogens including lysergic acid diethylamide (LSD) and psilocybin produce significant and sustained reductions of depressive symptoms and anxiety, along with increases in quality of life, and life meaning in patients suffering from life-threatening diseases. Additionally, serotonergic hallucinogens may produce antinociceptive effects. Objective and Design: The study aims to evaluate effects of LSD on psychosocial distress in 60 patients suffering from an advanced or end-stage fatal disease with a life expectancy ≥12wks and ≤2yrs in an active placebo-controlled double-blind parallel study. Patients will be allocated in a 2:1 ratio to one of the two intervention arms receiving either two moderate to high doses of LSD (100 µg and 100 µg or 100 µg and 200 µg) as intervention and two low doses of LSD (25 µg and 25 µg) as active-placebo control.